LakeShore Biopharma Co., Ltd

Delisted (Nasdaq: YS): renamed LakeShore Biopharma, taken private 2026-06-24

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
Rabies virus antigens (poly I:C-based adjuvant)Vaccine
Infectious Disease
Rabies Prevention and Post-Exposure Prophylaxis
YS-ON-001No recent activity
Phase 1
TLR3 (poly I:C adjuvant)Biologic (subtype unspecified)
Solid Tumors
Advanced Solid Tumors

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

7 November 2024Filing submittedPIKA Rabies VaccineBLA submission to Pakistan's DRAP initiated
PK, DRAP · LakeShore Biopharma · Source ↗
9 April 2024Topline resultPIKA Rabies VaccinePivotal Phase 3 interim analysis meets primary endpoints
YS Biopharma (now LakeShore Biopharma) · Source ↗

Financial reports

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$85M$20M$15M$3.5Mreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$80M$42M$34M$15Mreport ↗
2023-FY$100M$46M$54M$5.3Mreport ↗
2022-FY$79M$33M$43M$4.1Mreport ↗
2021-FY$38M$14M$59M$7.1Mreport ↗